Siegel, C. H. & Sammaritano, L. R. Systemic lupus erythematosus: a review. JAMA 3311480–1491 (2024).
Google Scholar
Fanouriakis, A. et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann. Rheum. Dis. 78736–745 (2019).
Google Scholar
Mougiakakos, D. et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N. Engl. J. Med. 385567–569 (2021).
Google Scholar
Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Night. With. 282124–2132 (2022).
Google Scholar
Muller, F. et al. CD19 CAR T-cell therapy in autoimmune disease—a case series with follow-up. N. Engl. J. Med. 390687–700 (2024).
Google Scholar
Zhang, W. et al. Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR. Stem Cell Rev. Rep. 172120–2123 (2021).
Google Scholar
Wang, W. et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann. Rheum. Dis. 831304–1314 (2024).
Google Scholar
Chen, W. et al. Distinct transcriptomes and autocrine cytokines underpin maturation and survival of antibody-secreting cells in systemic lupus erythematosus. Nat. Common. 151899 (2024).
Google Scholar
Taddeo, A. et al. Long-lived plasma cells are early and constantly generated in New Zealand Black/New Zealand White F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors. Arthritis Res. Ther. 1739 (2015).
Google Scholar
Hoyer, B. F. et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J. Exp. With. 1991577–1584 (2004).
Google Scholar
Jacobi, A. M. et al. HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 69305–308 (2010).
Google Scholar
Anolik, J. H. et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 503580–3590 (2004).
Google Scholar
Halliley, J. L. et al. Long-lived plasma cells are contained within the CD19−CD38hiCD138+ subset in human bone marrow. Immunity 43132–145 (2015).
Google Scholar
Qin, C. et al. Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity. Sci. Immunol. 9eadj9730 (2024).
Google Scholar
Crow, M. K. Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. Ann. Rheum. Dis. 82999–1014 (2023).
Google Scholar
Deng, Y. et al. Expression characteristics of interferon-stimulated genes and possible regulatory mechanisms in lupus patients using transcriptomics analyses. EBioMedicine 70103477 (2021).
Google Scholar
Schoggins, J. W. et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472481–485 (2011).
Google Scholar
Vincent, F. B., Morand, E. F., Schneider, P. & Mackay, F. The BAFF/APRIL system in SLE pathogenesis. Nat. Rev. Rheumatol. 10365–373 (2014).
Google Scholar
Yan, Z. et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Landett flash. 6e521 -e529 (2019).
Google Scholar
Yang, C. et al. Allogeneic anti-CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus. Cell Res. 35607–609 (2025).
Shu, J. et al. Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial. EClinicalMedicine 83103229 (2025).
Google Scholar
An, L. et al. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy. BMC Cancer 22393 (2022).
Google Scholar
Zhang, M. et al. Risk factors associated with durable progression-free survival in patients with relapsed or refractory multiple myeloma treated with anti-BCMA CAR T-cell therapy. Clin. Cancer Res. 276384–6392 (2021).
Google Scholar
Song, F. et al. Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL. J. Immunother. Cancer 11e005701 (2023).
Google Scholar
Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transpl. 25625–638 (2019).
Google Scholar
